Business, energy, technology, markets and global industry news from Business News Today

BostonGene

PharmaDeviceNews BostonGene
BostonGene and Kyoto University are applying AI-powered biomarker analysis to a Phase II trial of ICI-PDT combination therapy for advanced gastrointestinal cancers. Representative image.
Pharma & Biotech

Can BostonGene’s AI reveal which gastrointestinal cancer patients will benefit from ICI-PDT therapy?

BostonGene and Kyoto University will use multiomic AI to seek response biomarkers in a Phase II ICI-PDT trial for advanced GI cancers.

Read More
Medical Devices & Diagnostics

BostonGene AI framework identifies actionable targets in 65% of cancer of unknown primary cases at USCAP 2026

BostonGene presents multimodal AI CUP framework at USCAP 2026, identifying actionable targets in 65%+ of patients. Read the analysis.

Read More